

Precision Medicine Global Market Expected to Reach \$88 Billion at CAGR of 12% by Forecasts Period 2022

Wiseguyreports.Com Publish Market Research Report On-“Precision Medicine Global Market Expected to Reach \$88 Billion at CAGR of 12% by Forecasts Period 2022”.

PUNE, INDIA, October 9, 2017
/EINPresswire.com/ --

[Precision Medicine Market 2017](#)

The advancement and innovation of new healthcare technologies are developing the platform for the growth of precision medicine market. Since, the announcement of 'Precision Medicine Initiative' by the president Barack Obama in January end, 2015, a large number of research and developments are being done for the development of precise drugs, targeted therapeutics, and laboratory tests. Presently, the main focus of the government initiatives is toward oncology, but it is anticipated to target almost all therapeutic area affected by genetic mutations.

The global precision medicine market is expected to reach \$ 88 billion by 2022 at a CAGR of 12.0% during the forecast period.

On the basis of sub-markets, Pharmacogenomics is by far the fastest growing segment of global precision medicine market and it is expected to reach \$12.0 billion by 2022. Based on therapeutics, cancer commands the largest market share of global precision medicine market and it is expected to grow at a CAGR of 11.8% during the period 2015 to 2022

The Americas dominated the global market in 2014 and accounted for \$20.63 billion due to the advancement of gene mapping technologies and increasing precision medicine solutions.

Europe and APAC are estimated to show a high growth by the end of forecast period, where large numbers of developments in precision medicine have been noticed in the last few years are. In addition to this, APAC region is also predicted to grow at the highest CAGR of 14.34% from 2015 to 2022.

Request a Sample Report @ <https://www.wiseguyreports.com/sample-request/826425-global-precision-medicine-market-estimate-and-forecast-through-2015-2022>



Key Players

The leading market players in the global precision medicine market include; Abbott Laboratories (U.S), Almac Group, Ltd. (U.K.), ASURAGEN, Inc. (U.S.), bioMérieux SA (France), Cepheid Inc. (U.S.), GE Healthcare (U.S), GlaxoSmithKline Plc (GSK) (U.K.), Johnson & Johnson (U.S) Medtronic (U.S.) and others.

STUDY OBJECTIVES OF PRECISION MEDICINE MARKET DEVELOPMENT AND DEMAND FORECAST TO 2022 MARKET

- Ø To provide insights about factors, influencing and affecting the market growth.
- Ø To provide historically and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries.
- Ø To provide historically and forecast revenue of the market segments based on products, and sub-segment for global precision medicine market.
- Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.
- Ø To provide economic factors that influence the global precision medicine market.

Target Audience

- Pharmaceutical companies
 - Research Laboratories
 - Hospitals & Clinics
 - Service Suppliers
 - Potential Investors
-Continued

Any Query, Submit Here @ <https://www.wiseguyreports.com/enquiry/826425-global-precision-medicine-market-estimate-and-forecast-through-2015-2022>

Table of Contents –Analysis of Key Points

1	REPORT SCOPE	
2	EXECUTIVE SUMMARY	
3	MARKET OVERVIEW	
4	MARKET DYNAMICS	
5	INDUSTRY DYNAMICS	
6	CONSORTIUMS, CERTIFICATION, REGULATIONS, AND STANDARDS	
7	GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS	
8	GLOBAL PRECISION MEDICINE MARKET BY SUB-MARKETS	128
9	GLOBAL PRECISION MEDICINE MARKET BY THERAPEUTICS	162
10	GLOBAL PRECISION MEDICINE MARKET BY GEOGRAPHY	202
11	COMPANY PROFILES	227
11.1	ABBOTT LABORATORIES	227
11.1.1	OVERVIEW	227
11.1.2	FINANCIALS	228
11.1.2.1	Overall Financials	228
11.1.2.2	Financials by Segment	228
11.1.2.3	Financials by Region	229
11.1.2.4	Key Developments	229
11.1.3	SWOT ANALYSIS	231
11.2	ALMAC GROUP, LTD.	232
11.2.1	OVERVIEW	232
11.2.2	FINANCIALS	232

11.2.3 KEY DEVELOPMENTS	233
11.2.4 SWOT ANALYSIS	234
11.3 ASURAGEN, INC.	235
11.3.1 OVERVIEW	235
11.3.2 FINANCIALS	235
11.3.3 KEY DEVELOPMENTS	236
11.3.4 SWOT ANALYSIS	237
11.4 BIOMÉRIEUX SA	238
11.4.1 OVERVIEW	238
11.4.2 FINANCIALS	239
11.4.2.1 Overall Financials	239
11.4.2.2 Financials By Region	239
11.4.2.3 Financials By Segment	240
11.4.3 KEY DEVELOPMENTS	240
11.4.4 SWOT ANALYSIS	242
11.5 CEPHEID INC.	243
11.5.1 OVERVIEW	243
11.5.2 FINANCIALS	244
11.5.2.1 Overall Financials	244
11.5.2.2 Net Revenue By Segment	245
11.5.2.3 Net Revenue By Region	245
11.5.3 KEY DEVELOPMENTS	246
11.5.4 SWOT ANALYSIS	247
.....Continued	

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.